Riferminogene pecaplasmide

Drug Profile

Riferminogene pecaplasmide

Alternative Names: Cardiovascular gene therapy - sanofi-aventis; Cardiovascular therapeutic protein - sanofi-aventis; DNA-based delivery of Fibroblast Growth Factor 1 (FGF-1) - sanofi-aventis; FGF-1 gene therapy; NV1-FGF; Riferminogen pecaplasmid; Temusi; XRP 0038

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Developer Sanofi; sanofi-aventis
  • Class Anti-ischaemics; Gene therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Australia (IM)
  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Belarus (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top